The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s (NYSE:LLY) oral obesity pill, orforglipron. Roche Holdings AG (OTC ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Eli Lilly’s daily anti-obesity pill orforglipron appears to be as good at spurring weight loss and lowering blood sugar in diabetes patients as popular injectable GLP-1 drugs like Ozempic ...

Could the long-running obesity drugs leadership anchored by the Denmark-headquartered Novo Nordisk (NVO) be finally coming to an end? While arch rival Eli Lilly and Company (LLY) spent most of the ...

The Danish drugmaker on Friday abruptly announced that longtime CEO Lars Fruergaard Jørgensen is stepping down, as its obesity injection Wegovy loses ground to Eli Lilly 's rival treatment, Zepbound.

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly.

But investor enthusiasm has faded after Eli Lilly gained a bigger share of the market and clinical trial data on Novo Nordisk's next wave of obesity drugs underwhelmed investors.